Page 122 - Read Online

Muñoz-Martínez et al. Hepatoma Res 2022;8:30 https://dx.doi.org/10.20517/2394-5079.2022.22 Page 11 of 11

44. Trikudanathan G, Navaneethan U, Njei B, Vargo JJ, Parsi MA. Diagnostic yield of bile duct brushings for cholangiocarcinoma in
primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 2014;79:783-9. DOI PubMed
45. Navaneethan U, Njei B, Venkatesh PG, Vargo JJ, Parsi MA. Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in
primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 2014;79:943-950.e3. DOI PubMed
46. Njei B, McCarty TR, Varadarajulu S, Navaneethan U. Systematic review with meta-analysis: endoscopic retrograde
cholangiopancreatography-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Aliment
Pharmacol Ther 2016;44:1139-51. DOI PubMed
47. Keihanian T, Barakat MT, Tejaswi S, et al. Role of Endoscopic Retrograde Cholangiopancreatography in the Diagnosis and
Management of Cholestatic Liver Diseases. Clin Liver Dis 2022;26:51-67. DOI PubMed
48. Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A
systematic review and meta-analysis. J Hepatol 2020;72:95-103. DOI PubMed
49. Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control
2017;24:1073274817729245. DOI PubMed PMC
50. Darnell A, Rimola J, Belmonte E, et al. Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in
cirrhotic patients. Eur Radiol 2021;31:4794-803. DOI PubMed
51. Sithithaworn P, Yongvanit P, Duenngai K, Kiatsopit N, Pairojkul C. Roles of liver fluke infection as risk factor for
cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2014;21:301-8. DOI PubMed
52. Khuntikeo N, Loilome W, Thinkhamrop B, Chamadol N, Yongvanit P. A Comprehensive Public Health Conceptual Framework and
Strategy to Effectively Combat Cholangiocarcinoma in Thailand. PLoS Negl Trop Dis 2016;10:e0004293. DOI PubMed PMC
53. Khuntikeo N, Koonmee S, Sa-Ngiamwibool P, et al. A comparison of the proportion of early stage cholangiocarcinoma found in an
ultrasound-screening program compared to walk-in patients. HPB (Oxford) 2020;22:874-83. DOI PubMed
54. Sungkasubun P, Siripongsakun S, Akkarachinorate K, et al. Ultrasound screening for cholangiocarcinoma could detect premalignant
lesions and early-stage diseases with survival benefits: a population-based prospective study of 4,225 subjects in an endemic area.
BMC Cancer 2016;16:346. DOI PubMed PMC
55. Valle JW, Kelley RK, Nervi B, Oh D, Zhu AX. Biliary tract cancer. The Lancet 2021;397:428-44. DOI
56. Yang CM, Shu J. Cholangiocarcinoma Evaluation via Imaging and Artificial Intelligence. Oncology 2021;99:72-83. DOI PubMed
57. Granata V, Fusco R, Setola SV, et al. An update on radiomics techniques in primary liver cancers. Infect Agent Cancer 2022;17:6.
DOI PubMed PMC
58. Macias RIR, Cardinale V, Kendall TJ, et al. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future
directions. Gut 2022;71:1669-83. DOI PubMed
59. Arechederra M, Rullán M, Amat I, et al. Next-generation sequencing of bile cell-free DNA for the early detection of patients with
malignant biliary strictures. Gut 2022;71:1141-51. DOI PubMed PMC
60. Moeckli B, Ivanics T, Claasen M, Toso C, Sapisochin G. Recent developments and ongoing trials in transplant oncology. Liver Int
2020;40:2326-44. DOI PubMed
61. Zhu AX, Macarulla T, Javle MM, et al. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced
Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol 2021;7:1669-77. DOI
PubMed PMC
62. Abou-alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma:
a multicentre, open-label, phase 2 study. The Lancet Oncology 2020;21:671-84. DOI PubMed PMC
63. Oh DY, He AR, Qin S, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with
gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J Clin Oncol 2022;40:378-
378. DOI